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Abstract
Background: We designed two telemonitoring text and voice
messaging interventions, EpxDecolonization (EpxDecol) and
EpxWound, to improve management of orthopedic joint re-
placement patients at Washington University. We reviewed
the use of these tools for a period of 88 weeks.
Methods: Cohorts of 1,392 and 1,753 participants completed
EpxDecol and EpxWound, respectively. All patients who
completed EpxDecol also completed EpxWound. We assessed
patient use of and satisfaction with these interventions. A
return on investment (ROI) analysis was conducted to deter-
mine the cost savings generated by EpxWound and EpxDecol.
Results: The proportions of patients who responded daily
to EpxDecol and EpxWound were 91.9% and 77.7%, respec-
tively, over the lengths of each intervention. The percent of
daily responders declined <5% during each intervention. Ulti-
mately, 88.4% of EpxDecol patients and 67.8% of EpxWound
patients responded to ‡80% of all messages. Median patient
survey responses (n = 1,246) were 9/9 (best possible) for care,
8/9 for improved communication, and 5/9 (perfect number) for
number of messages received. ROI analysis for this 88-week
period showed that using EpxDecol and EpxWound to engage
patients (instead of nurses calling patients) saved the equiva-
lent of 2.275 full-time nursing equivalents per week. We cal-
culated net savings of $260,348 with an ROI of 14.85x for
1,753 patients over 88 weeks. One-year cost savings from
these interventions were $153,800 with an ROI of 14.79x.
Conclusions: EpxDecol and EpxWound may serve important
roles in the perioperative process for orthopedic joint reconstruc-
tion surgery givenhighpatient usage of and satisfactionwith these
interventions. Implementing EpxDecol and EpxWound for a large
patient population could yield substantial cost savings and ROI.




urgical site infections (SSIs) are the most frequent
and costly hospital-acquired infection and may
yield additional annual healthcare costs of $3.5–10
billion.1,2 SSIs prove especially problematic in or-
thopedic patients.3 By 2020, there will be a predicted 70,000
total hip and knee arthroplasty SSIs requiring additional
treatment, with an associated annual cost of $1.62 billion.4
To supplement postoperative measures designed to reduce
SSIs, many healthcare providers now use a preoperative de-
colonization protocol for patients undergoing elective sur-
gery. Most protocols attempt to decolonize Staphylococcus
aureus with a combination of daily chlorohexidine gluco-
nate skin cleanser and intranasal mupirocin, which has been
shown to diminish SSIs due to S. aureus in patients under-
going total joint replacement.3,5 Unfortunately, complete
adherence to these protocols may be infrequent, potentially as
low as 31.1%.6 Short message service (SMS) text message
reminders have proven useful for increasing medication ad-
herence for diabetic patients7 and dialysis adherence for
chronic hemodialysis patients.8 Meta-analysis has found
that mobile interventions may increase medication adherence
by 22%.9 These data suggest that a preoperative automated
messaging platform with daily reminders could address pa-
tient adherence challenges and improve decolonization rates.
Moreover, automated messaging interventions could address
postoperative complications, particularly for SSIs. Surveys of
surgery patients at time of discharge reveal concerns about
wound care, monitoring of postoperative complications, and
patients’ ability to contact healthcare providers should prob-
lems occur.10,11 Patients also believe that mobile interventions
could address postdischarge challenges by allowing for more















































frequent, thorough, and convenient follow-up.11 Using auto-
mated telemedicine interventions to solicit patient-reported
information has been shown to improve management of he-
moglobin A1c in diabetic patients.12 However, SMS or phone
call platforms have not been used as often for SSI reduction.13
To address these inadequacies, we developed two auto-
mated messaging systems named ‘‘EpxDecolonization’’ (Epx-
Decol) and ‘‘EpxWound’’ for the Orthopedic Adult Joint
Reconstruction Service at Barnes-Jewish Hospital in St. Louis,
MO. EpxDecol was developed in concordance with the de-
colonization protocol already in place at Barnes-Jewish, and
EpxWound was developed to improve postoperative moni-
toring of pain and symptoms suggestive of a potential SSI. The
infrastructure for EpxDecol and EpxWound was provided by
Epharmix, a startup company located in St. Louis. This study
was an expansion of a prior pilot trial for EpxDecol and
EpxWound.14 We investigated the usability of and patient
satisfaction with EpxDecol and EpxWound for an 88-week
period. Furthermore, we determined the return on investment
(ROI) generated on using these automated systems in place of
manual nurse follow-up with patients by phone call.
Methods
PATIENT ENROLLMENT
Patient enrollment in EpxDecol and EpxWound was clas-
sified as a clinical pilot, not a quality improvement research
study, by the Washington University School of Medicine
Institutional Review Board. The pilot trial spanned from
November 29, 2015 to September 3, 2016 (40 weeks) and
included about 650 patients.14 The pilot trial was subse-
quently expanded, and the data for this article were collected
between November 29, 2015 and August 7, 2017. Patients
undergoing a hip or knee replacement at Barnes-Jewish
Hospital were offered the choice to enroll in Epharmix and
consented to the use of these interventions alongside usual
standard of care. Patients were excluded if they did not speak
English or did not have access to a phone (any phone, in-
cluding a landline or nonsmartphone). Participants elected to
receive messages from EpxDecol, EpxWound, or both. They
chose a preferred mode of contact (either phone call or SMS
text messaging) and the time of day at which they received
messages. Patients could drop out of each intervention by
replying ‘‘stop’’ to the system at any point.
INTERVENTION DESIGN
Figure 1 depicts the message algorithm for EpxDecol. Start-
ing 6 days before surgery, EpxDecol asked patients if they had
picked up their prescribed decolonization supplies (mupirocin
nasal ointment and chlorhexidine gluconate cleanser) from the
pharmacy (day 0). If the patient had not received their supplies
5 days before surgery, an alert was sent to the nurse in charge
of their care. Beginning 5 days before surgery, those patients
who had picked up their supplies were asked daily if they had
used their decolonization supplies as specified by their physi-
cian (days 1–5). Two separate messages were sent—one asking
about the nasal ointment and another about the chlorhexidine
cleanser. All responses could be monitored by a member of the
medical team. An alert was not generated if a patient did not use
their decolonization supplies.
Figure 1 also depicts the message algorithm for EpxWound.
EpxWound was designed to identify SSIs in the time frame
between the patient’s discharge and their 2-week follow-up
appointment by tracking pain and wound symptoms. This
intervention sent daily automated messages consecutively
from postoperative day (POD) 5 to POD 19. Patients were asked
daily about their postoperative pain, wound status (increased
redness, drainage, or odor), and body temperature. An alert
was sent to the nurse in charge of a patient’s care if that patient
reported increased redness, drainage, or odor; a fever ‡101F;
or significant pain. If a patient generated an alert while using
either EpxDecol or EpxWound, their nurse received an e-mail
notifying the nurse to follow-up with that patient. An alert
notification was also created in the Epharmix portal. After an
alert, the medical team contacted the patient through phone
call within 2 h (if during business hours) or the following
morning (if after hours).
Two weeks after using both interventions, an automated
electronic survey using a 1–9 response scale was delivered to
collect patients’ opinions on their care (1 = terrible, 5 = aver-
age, and 9 = excellent), the number of messages they received
(1 = too few, 5 = perfect amount, and 9 = too many), and
whether they felt that our interventions improved communi-
cation with their doctors (1 = significantly worsened, 5 = no
change, and 9 = significantly improved). Only fully completed
survey responses were analyzed.
DATA AND STATISTICAL ANALYSIS
The primary outcome was daily response rates for each
automated system. Secondary outcomes were patient satis-
faction with the interventions, the number of alerts generated
by each intervention, and an ROI calculation. A daily response
rate was calculated for each patient during the months of
November 2015 to August 2017 and was defined as a response
to at least one message during that day. For the automated
survey results, the medians, means, and standard deviations
(SDs) for participants’ assessed scores were calculated in Mi-
crosoft Excel (Redmond, WA).
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Fig. 1. Message algorithms for EpxDecol and EpxWound (courtesy of Epharmix). For EpxDecol, two separate messages were sent
for the 5 days before surgery: one asking about use of the nasal ointment and another about the chlorhexidine cleanser. EpxDecol,
EpxDecolonization.
















































An ROI calculation (Table 1) was conducted to determine
the cost savings and ROI produced by EpxDecol and Epx-
Wound for our 88-week period and for 1 year. ROI was based
on the estimated average time required to manually call each
patient for EpxDecol and EpxWound in lieu of automated
messages. We conservatively estimated that each EpxDecol
phone call would take 10 min and each EpxWound phone call
would take 15 min. These estimates were based on nurses’
evaluations of how long a call would have to be to obtain
patient answers to every question posed by EpxDecol and
EpxWound. We calculated how many full-time nursing
equivalents (FTEs) were saved using Epharmix by determining
how much time would be spent on making calls for each in-
tervention in 1 week. One FTE was defined as one nurse
working a 40-h week. Weekly time spent on EpxDecol and
EpxWound equaled 60 and 225 min per patient, respectively,
multiplied by the average number of patients enrolled per
week for each intervention. The weekly times for EpxDecol
and EpxWound were summed and divided by 40 h to yield the
FTE saved. The Price Per FTE was the cost of hiring a nurse to
work for a certain number of weeks. For this calculation we
used $1,388 for a nurse’s weekly wage, based on the average
annual American nursing salary of $72,180.15 There is a $10
per month cost to enroll a patient in any number of Epharmix
interventions (i.e., in EpxDecol, EpxWound, or both). To cal-
culate Total Cost Savings, we multiplied the Price per FTE by
the number of FTE saved and then subtracted the cost of en-
rolling every patient in Epharmix for a given time period. ROI
equaled Total Cost Savings divided by the cost of enrolling all
patients in Epharmix over that time period.
Results
PATIENT OVERVIEW
In total over the 88-week period, 1,392 patients were en-
rolled in EpxDecol, and 1,753 patients were enrolled in Epx-
Wound. On average, 16 patients were enrolled per week in
EpxDecol and 20 per week in EpxWound. For EpxDecol, 1,070
patients (77%, 1,070/1,392) elected to receive text messages,
while 322 (23%, 322/1,392) chose phone calls. For Epx-
Wound, 1,302 patients (74%, 1,302/1,753) received text
messages, and 451 (26%, 451/1,753) chose phone calls. Ulti-
mately, 28 patients (2%, 28/1,392) and 68 patients (3.9%, 68/
1,753) dropped out of EpxDecol and EpxWound, respectively,
over the course of each intervention. EpxDecol saw the
highest dropout rate (eight patients, 0.58%, 8/1,382) on day 2;
EpxWound had the highest dropout rate (16 patients, 0.91%,
16/1,753) on day 0 (POD 5).
The average SSI rates for the Washington University Or-
thopedic Surgery Department over this period were 0.31%
and 0.47% for primary hip and knee surgeries, respectively.
The department averaged 25 hip or knee replacements
per week. Given constraints as a clinical pilot, both the
enrollment percentage for EpxDecol and EpxWound during
this study and the number of patients who underwent knee
replacement versus hip replacement were unobtainable.
About 99% of patients elected to receive their messages at
6 PM.
RESPONSE PROPORTIONS
The proportion of EpxDecol messages to which patients
responded at least once per day was 91.9% (7,600 responses/
8,266 total messages). The proportion of daily responders
declined less than 5% over the course of the interven-
tion, with a high of 94.2% on day 0 (1,312/1,392) and a low
of 90.3% (1,232/1,364) on day 5 (Fig. 2). Ultimately, 1,230
patients (88.4%, 1,230/1,392) responded to at least 80% of
all EpxDecol sessions, while 1,097 (78.8%, 1,097/1,392)
responded to 90–100% of all sessions (Fig. 3). The propor-
tion of patients responding to questions about using the
nasal ointment was 91.9% (7,600 responses/8,266 total
messages) compared to 87.5% (7,230 responses/8,266 total
messages) for the questions regarding use of the chlorhex-
idine cleanser. Concerning self-reported decolonization
protocol adherence, 89.5% (1,115/1,246) of patients applied
their nasal ointment as instructed on day 1, and 76% (947/
1,246) used their nasal ointment every day for days 1–5.
For the chlorhexidine cleanser, 67% (820/1,222) used their
cleanser as instructed on day 1 and 50.8% (621/1,222) used
it every day for days 1–5. These EpxDecol adherence values
were calculated using only patients who reported that
Table 1. Equations for Return on Investment Analysis
EpxDecol = (6 calls/patient) · (10 min/call) = 60 min/patient
EpxWound = (15 calls/patient) · (15 min/call) = 225 min/patient
Weekly time per intervention
EpxDecol = (60 min/patient) · (average No. of patients enrolled/week)
EpxWound = (225 min/patient) · (average No. of patients enrolled/week)
FTE saved = (EpxDecol weekly time + EpxWound weekly time)/(40 h/week)
Price per FTE = (nurse weekly wage) · (time period in weeks)
Total cost savings = (price per FTE · FTE saved) - $10(total No. of patients
enrolled in a given time period)
ROI = total cost savings/$10(total patients enrolled in a given time period)
EpxDecol, EpxDecolonization; FTE, full time nursing equivalent; ROI, return on
investment.
YAHANDA ET AL.















































they had picked up their decolonization supplies from the
pharmacy.
For EpxWound, the proportion of messages to which pa-
tients responded was 77.7% (19,914 responses/25,642 total
messages). Daily responses to EpxWound declined <7% at any
point during the intervention. The highest daily response
proportion was 80.7% (1,414/1,753) on day 0 (POD 5) and the
lowest was 74.4% (1,257/1,689) on day 13 (POD 18) (Fig. 2).
The response proportion on day 14 (POD 19) was 76.8%
(1,295/1,685). When broken down by week, the average pro-
portions of responses for EpxWound were 79% (9,542/12,074)
for week 1 and 76.4% (10,372/13,568) for week 2. Overall,
1,189 patients (67.8%, 1,189/
1,753) responded to at least 80%
of all EpxWound sessions and
908 patients (51.8%, 908/1,753)
responded to 90–100% of all ses-
sions (Fig. 3).
ALERTS
There were 8,266 total EpxDe-
col messages sent during the 88-
week period. Seventy-five alerts
were generated among all Epx-
Decol patients, resulting in an
alert rate of 5.4% (75/1,392). Of
these, 53 alerts (70.7%, 53/75)
were generated on day 0. All alerts
corresponded to patients replying
‘‘No’’ to the questions regarding
the acquisition of their medications from the pharmacy.
A total of 25,642 messages were sent for EpxWound. In all,
128 alerts were generated among all EpxWound patients, re-
sulting in an alert rate of 7.3% (128/1,753). Twenty-eight
alerts were generated by patients calling their physician’s
office and were not included in our analysis, leaving a patient-
generated alert rate of 5.7% (100/1,753) (Fig. 4). The majority
of alerts (n = 51, 51%) came from days 0 to 4 (POD 5–9). The
highest number of alerts was generated on day 2 (POD 7,
n = 14, 14%, 14/100) and day 5 (POD 10, n = 11, 11%, 11/100).
Ninety-one of the 100 alerts (91%) were generated by patients
who reported increased pain, and 9 alerts (9%) were generated
by patients who claimed signs of
wound degeneration (increased
drainage, redness, or odor with or
without an accompanying fever).
SATISFACTION WITH THE
INTERVENTIONS
A cohort of 1,246 patients
completed postintervention sur-
veys. The median response for
how patients rated the care they
received was 9/9 (the best possible
score), and the mean response was
8.6 (SD = 1.2) (Fig. 5). There was a
median score of 8/9 with respect
to how Epharmix improved com-
munication with physicians, with
a mean response of 7.2 (SD = 2.1).
The median score for the numberFig. 3. Distribution of percentage of sessions answered by patients.
Fig. 2. Average proportion of patients who responded on each day of the intervention over the
88-week period.
USE AND COST SAVINGS OF AUTOMATED MESSAGE SYSTEMS















































of messages received during each intervention was 5/9 (the best
possible score, with 0 = too few messages and 9 = too many
messages) with a mean of 5.5 (SD = 1.5). Due to IRB constraints
as a pilot study, it was not possible to formally survey nurses to
quantify their satisfaction with our automated systems. Anec-
dotally, EpxDecol and EpxWound were appreciated by nurses
as a way to improve and streamline patient care.
RETURN ON INVESTMENT
ROI results can be seen in Table 2. Without the benefit of an
automated messaging system, a nurse would be expected on
average to spend 60min for EpxDecol and 225 min for Epx-
Wound per patient. Given mean enrollment of 16 patients per
week for EpxDecol and 20 patients per week for EpxWound,
this would result in 91h of phone calls or 2.275 FTE. Assuming
an annual nursing salary of $72,180 and subtracting the
$17,530 that it would cost to enroll 1,753 patients in Epharmix,
we found that use of EpxDecol and EpxWound to contact pa-
tients saved the Orthopedic Surgery Department $260,363 over
the course of our 88-week time period. This corresponded to an
ROI of 14.85x (1,485%). On an annual basis, based on 1,040
enrolled patients (20 patients/week for 52 weeks), cost savings
were $153,800, and the ROI was 14.79x (1,479%).
Discussion
Currently, patients are responsible for following pre- and
postoperative protocols based on instructions that they are
given before surgery and after discharge. This system is in-
herently inefficient and prone to error and nonadherence.
Interventions such as EpxDecol and EpxWound are needed
to increase patient adherence and to more effectively inter-
face with patients outside of the hospital. Multiple digital
platforms exist that utilize email or portal sites to enhance
patient–provider communica-
tion.16 Nevertheless, these ar-
rangements may fall short because
they require smartphone or com-
puter access, which are unavail-
able to many patients, particularly
those of lower socioeconomic
status.16 Use of an SMS- or phone
call-based intervention, on the
other hand, allows providers to
engage a larger portion of patients
due to the near-ubiquitous capa-
bility of all phones to answer basic
text messages or phone calls.17
These results suggest that
EpxDecol and EpxWound effec-
tively engage a broad range of patients in the perioperative
process, as demonstrated through high response proportions
that declined minimally over the length of each intervention.
The overall proportions of patients who responded daily were
nearly 92% and 78% for EpxDecol and EpxWound, respec-
tively. These numbers are higher than those for similar in-
terventions mentioned in the literature.18,19 Self-reported
measures of adherence to our decolonization protocol were
higher than adherence rates that have been previously re-
ported for similar decolonization therapies,6,20 although the
validity of patient-reported adherence rates could be ques-
tioned. We believe that adherence to the chlorhexidine
cleanser aspect of EpxDecol may be an underestimate of true
adherence. The disparity in patient-reported adherence re-
garding use of their nasal spray (76% used every day) versus
their cleanser (50.8% used every day), despite similar average
response proportions to both questions (nasal spray: 91.9%,
cleanser: 87.5%), suggests that patients are either much less
adherent to using their Scrub Care or that our message timing
was suboptimal. Since about 99% of patients received Epx-
Decol messages at 6 PM, we hypothesize that a sizable pro-
portion of these patients planned on using their scrub care
later in the night, but had not yet taken a shower. Conse-
quently, they responded that they had not completed their
decolonization for that day.
The high levels of patient satisfaction reported with Epx-
Decol and EpxWound indicate that patients value these in-
terventions despite the fact that patients received automated
messages instead of personal phone calls. Indeed, automated
messages made patients feel like they had improved com-
munication with their physician. Patients, for the most part,
did not experience notable message fatigue and reported
that they received almost the perfect number of inquiries,
Fig. 4. The percentage of EpxWound alerts generated per day.
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Fig. 5. Patient satisfaction with EpxDecol and EpxWound. On a scale of 1–9, patients rated their care provided by their medical care team
(1 = terrible, 5 = average, and 9 = excellent), whether EpxDecol and EpxWound improved communication with their doctor (1 = significantly
worsened, 5 = no change, and 9 = significantly improved), and their satisfaction with the number of messages that they received (1 = too
few, 5 = perfect amount, and 9 = too many).















































suggesting Epharmix’s role as a helpful supplement to dis-
charge instructions.
The cost savings and ROI analysis indicated that using Epx-
Decol and EpxWound may have helped the Barnes-Jewish Or-
thopedic Department save $260,363 over an 88-week span, with
a yearly savings of $146,679. These numbers may be conser-
vative estimates. We assumed the average nursing salary across
theUnitedStates, but did not attempt to factor in benefits or other
supplementary costs that accompany hiring additional nurses.
This potentially reduced the reported cost savings and ROI.
LIMITATIONS
We could not fully clarify the effects of EpxDecol and
EpxWound beyond patient responses and patient satisfaction
and, thus, could not conclude any direct benefits from these
interventions. For EpxDecol, we were unable to verify if pa-
tients truly were using their decolonization materials as
specified and had to rely solely on patient responses. Since this
was chiefly a feasibility study, we could not compare decol-
onization adherence rates between a control group and an
intervention group. Our status as a clinical pilot prohibited
retrospective access to patient medical records; we therefore
could not determine the sensitivity and specificity of Epx-
Wound for identifying SSIs. Future studies of EpxDecol and
EpxWound will prospectively compare adherence rates with
control groups and examine the efficacy with which these
interventions may help prevent or catch SSIs. Our clinical
pilot status also blocked us from calculating the percentage of
patients who declined enrollment and which patients under-
went knee versus hip replacement. The volunteer structure of
this study may impart some bias upon our results: patients
who consented possibly were more likely to respond to in-
quiries from the interventions. Finally, the time at which pa-
tients received messages may have inadvertently affected
their responses to questions. We will consider adjusting
message timing in future studies.
Conclusion
EpxDecol and EpxWound may serve important roles in the
perioperative process for orthopedic joint reconstruction sur-
gery given high usage of and patient satisfaction with the in-
terventions. Anecdotally, nurses appreciated and recommend
these interventions. Meaningful cost savings and substantial
ROI may be realized by implementing these interventions in
place of manual calls to patients. Moving forward, in addition
to more prospective studies of EpxDecol and EpxWound in
orthopedic patient populations, we hope to expand these in-
terventions to other surgical subspecialties such as neurosur-
gery, colorectal, trauma, and cardiothoracic. Adapting this
technology to more surgical patients could have widespread
impacts on overall patient care and enable cost savings across
different departments.
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